NCT07729462
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
At risk: Primary completion moved 39 days later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 15, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 19 → 38 locations
- Minor Study sites: 19 to 21
- Minor Trial sites expanded: 4 → 19 locations
Notable Recruitment opened Show 6 more changesShow less
- Eligibility criteria expanded, about 22 words
- Primary completion pushed from Sep 12, 2028 to Oct 21, 2028
- Study completion pushed from Dec 11, 2028 to Jan 19, 2029
- Start date changed from estimate of Jul 29, 2026 to Aug 26, 2026
- Secondary endpoints: details revised at 6 of 7 entries
- Site details revised at 4 of 4 sites
- Minor Study sites: 2 to 4v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will receive rimegepant 75 mg orally disintegrating tablet (ODT) once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.
Participants will receive matching placebo once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.
Drugs: Rimegepant, Placebo
Sites
38 sites in 4 countries
United States 22, China 6, Israel 5, United Kingdom 5